Dr. Joshua E. Reuss

About Dr. Reuss

Dr. Joshua Eric Reuss leads efforts in thoracic medical oncology at MedStar Georgetown University Hospital. He treats people diagnosed with mesothelioma, lung cancer and thymoma. 

He collaborates with scientists to develop more effective treatments, boosting results for mesothelioma patients. Dr. Reuss received the Young Investigator Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology in 2019.​

Medical Education & Expertise

• MedStar Georgetown University Hospital 
• Johns Hopkins University School of Medicine (Fellowship)
• University of Virginia Medical Center (Residency)
• University of Rochester (M.D.)
• Brandeis University (B.A.)

Associations Awards & Recognition

• Board Certification, American Board of Internal Medicine, Medical Oncology​
• Selected Participant ASCO/AACR Methods in Clinical Cancer Research Workshop, 2018
• Best Fellows Abstract Oral Presentation IASLC Targeted Therapies of Lung Cancer Meeting, 2019
• Selected Participant FDA-ASCO Hematology and Oncology Fellows Day Workshop, 2019
• Visiting Fellow, Investigational Drug Branch, Cancer Therapy Evaluation Program of the NCI, 2019

• Young Investigator Award, Conquer Cancer Foundation of ASCO, 2019
• Research Award Recipient 3rd Annual EGFR Resisters Research Summit, 2021
• Selected Participant Journal of Clinical Oncology Precision Oncology Trainee Reviewer Mentoring Program, 2022

Why Choose Dr. Reuss for Mesothelioma?

Dr. Reuss develops and leads cutting-edge clinical trials that advance patient care and treatment. His research on immunotherapy response and resistance help specialists ensure therapies are as effective as possible.

Patients can join these clinical trials at MedStar Georgetown Cancer Institute. This NCI-designated center gives top cancer care in Washington, DC.​ Dr. Reuss’s passion and dedication to thoracic medical oncology open the door to new care paths for people with mesothelioma.

Publications of Dr. Reuss

• Reuss, J. at al. (2025, July 17). Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1. Retrieved from https://ascopubs.org/doi/10.1200/JCO-25-01061
• Reuss, J. at al. (2025, February 12). Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis. Retrieved from https://ascopubs.org/doi/10.1200/OP-24-00788
• Reuss, J. at al. (2024, February 28). Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3. Retrieved from https://ascopubs.org/doi/10.1200/JCO.23.02746
• Reuss, J. at al. (2023, March 31).  Figure S2 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer. Retrieved from https://aacr.figshare.com/ndownloader/files/39941852
• Reuss, J. at al. (2020, September 13). Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. Retrieved from https://jitc.bmj.com/content/8/2/e001282